Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients

Pei Meng, Anna A. Rybczynska, Jiacong Wei, Miente Martijn Terpstra, Wim Timens, Ed Schuuring, T. Jeroen N. Hiltermann, Harry J.M. Groen, Anthonie J. van der Wekken, Anke van den Berg, Klaas Kok
doi: https://doi.org/10.1101/2021.01.26.21250013
Pei Meng
1Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna A. Rybczynska
2Department of Genetics, University Medical Centre Groningen, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiacong Wei
2Department of Genetics, University Medical Centre Groningen, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miente Martijn Terpstra
2Department of Genetics, University Medical Centre Groningen, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wim Timens
1Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ed Schuuring
1Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Jeroen N. Hiltermann
3Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harry J.M. Groen
3Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthonie J. van der Wekken
3Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anke van den Berg
1Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaas Kok
2Department of Genetics, University Medical Centre Groningen, University of Groningen, University Medical Centre Groningen, 9700RB Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: k.kok{at}umcg.nl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Nowadays, the detection of therapy-guiding aberrations such as EGFR mutations and ALK fusion genes in tumor tissue is common practice for lung cancer patients. The aim of this study is to explore the feasibility of detecting common therapy-guiding aberrations in RNA isolated from platelets.

Methods We applied a single primed enrichment-based targeted next generation sequencing (NGS) approach on 10 platelet RNA samples isolated from patients with active disease. In parallel, we applied RNA-based ddPCR focusing on EGFR p.(T790M), p.(L858R) and E19del, on KRAS codon 12 and 13 and on ALK-EML4/KIF5B fusions on 22 platelet RNA samples from patients with tumors known to harbor one of these drivers. For 11 cases ddPCR analysis of circulating cell free (cf)DNA from the same blood sample was performed in parallel.

Results Despite having good quality NGS data, none of the variants detected in the tumor biopsy were observed in platelet-derived RNA samples. Using the more sensitive ddPCR, we detected known aberrations in three of 22 platelet-derived RNA samples. EGFR mutant droplets were not observed in any of the seven platelet samples, while these mutations were detected in three of six cfDNA samples of which five were extracted from the same blood sample. KRAS mutant droplets were detected in three out of nine platelet RNA samples with fractional abundances of 0.07%, 0.11% and 0.55%. Analysis of five cfDNA samples from the same blood samples revealed KRAS-mutant droplets in four of them. Two of the four corresponding platelet RNA samples were also positive for mutant KRAS. No ALK fusion droplets were detected in seven platelet derived RNA samples.

Conclusions The level of tumor-derived RNA transcripts in platelets of non-small cell lung cancer patients was too low to be measured reliably for clinically relevant alterations in EGFR, KRAS and ALK fusion gene transcripts.

Competing Interest Statement

Ed Schuuring has performed lectures for Bio-Rad, Novartis, Roche, Biocartis, Illumina, Pfizer, AstraZeneca, and Agena Bioscience, is consultant in advisory boards for AstraZeneca, Roche, Pfizer, Novartis, Bayer, Lilly, BMS, Amgen, BioCartis, Illumina, Agena Bioscience and MSD/Merck, and received research grants from Pfizer, Biocartis, Agena Bioscience, BMS, Bio-Rad, Roche, Boehringer Ingelheim. Wim Timens reports fees to Institution for lectures or consultancy from Roche Diagnostics / Ventana, Merck Sharp Dohme, Bristol-Myers-Squibb, and AbbVie, outside the submitted work. Harry J M Groen reports grants from Boehringer-Ingelheim, Takeda, BMS, Novartis, Merck outside the submitted work. Anthonie van der Wekken has performed lectures for Lilly, Boehringer-Ingelheim, Pfizer, AstraZeneca, Roche (diagnostics) and Takeda, is consultant in advisory boards for Lilly, Boehringer-Ingelheim, Pfizer, AstraZeneca, Roche (diagnostics), Takeda and Janssen, received grants from Boehringer-Ingelheim, Pfizer, AstraZeneca, Roche and Takeda all outside the submitted work. Jeroen Hiltermann reports grants from AstraZeneca, Roche, BMS, outside the submitted work.

Funding Statement

This research was funded by the Dutch Cancer Society Grant: KWF grant (RUG2015-8044).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study ethics was approved by the OncoLifeS biobank committee (Biobank of cancer in UMCG). The biobank was approved by the UMCG research ethics committee. The study was conducted in accordance with the 1964 Helsinki declaration.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 28, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients
Pei Meng, Anna A. Rybczynska, Jiacong Wei, Miente Martijn Terpstra, Wim Timens, Ed Schuuring, T. Jeroen N. Hiltermann, Harry J.M. Groen, Anthonie J. van der Wekken, Anke van den Berg, Klaas Kok
medRxiv 2021.01.26.21250013; doi: https://doi.org/10.1101/2021.01.26.21250013
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients
Pei Meng, Anna A. Rybczynska, Jiacong Wei, Miente Martijn Terpstra, Wim Timens, Ed Schuuring, T. Jeroen N. Hiltermann, Harry J.M. Groen, Anthonie J. van der Wekken, Anke van den Berg, Klaas Kok
medRxiv 2021.01.26.21250013; doi: https://doi.org/10.1101/2021.01.26.21250013

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pathology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)